Kiniksa Pharmaceuticals

KNSA

Market cap $3.22B

LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. Greenwich Mean Time (9:30 a.m.

EQX, GDEN and KNSA have been added to the Zacks Rank #5 (Strong Sell) List on October 30, 2025.

Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180.9M (+61% YoY, +15% QoQ), prompting raised FY2025 guidance to $670–$675M. ARCALYST's efficacy and new ACC guidance support increased patient-months, leading to a more steady revenue stream and reposition users for longer-term use.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jonathan Kirshenbaum - Investor Relations Officer Sanj Patel - CEO & Chairman of the Board Ross Moat - Executive VP & Chief Commercial Officer Mark Ragosa - Senior VP & CFO John Paolini - Executive VP & Chief Medical Officer Conference Call Participants Mary Kate Davis Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division Nicholas Lorusso - TD Cowen, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division David Nierengarten - Wedbush Securities Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2025 Earnings Conference Call.

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to a loss of $0.18 per share a year ago.

– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today –

LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution.

LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis. KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α) and interleukin-1β (IL-1β).

Kiniksa Pharmaceuticals International, plc (KNSA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.